乌鸦传媒

GSK announced that belantamab mafodotin (Blenrep) plus bortezomib (Velcade) and dexamethasone improved overall survival in as compared with daratumumab (Darzalex) plus bortezomib and dexamethasone, coming full circle in a bid to return to the U.S. market after .

China-based BeiGene announced a rebranding as . (EndPoint News)

MRI guidance for led to a significant reduction in toxicity and improvement in patients' quality of life. (UCLA Health, European Urology)

In a small preliminary clinical study, an investigational cancer vaccine induced immune responses in hard-to-treat . (WashU Medicine, Genome Medicine)

Patients with prostate specific membrane antigen-positive lived significantly longer without disease progression when treated with the radioligand ¹⁷⁷Lu-PSMA-I&T versus hormonal therapy, Curium Pharmaceuticals announced.

Royal Philips announced FDA clearance of its detector-based spectral CT radiotherapy solution designed to deliver more .

A clinical trial of the targeted drug revumenib in relapsed/refractory NMP1-mutant met the primary endpoint of complete remission plus complete remission with partial hematological recovery, Syndax announced.

A virology scientist recounts the experience of with viruses she grew in a laboratory. (Inside Hook)

informed by ctDNA analysis led to significantly better overall survival in metastatic gastrointestinal cancers. (ESMO, Nature Medicine)

A 10-second, during surgery for brain cancer showed whether any cancer cells remained. (Michigan Medicine, Nature)

New insights into how a might help slow the progression of prostate cancer. (City of Hope)

Preliminary evidence of activity in emerged from an early-stage clinical trial of pembrolizumab (Keytruda) plus denileukin diftitox (Lymphir), Citius Pharma announced.

The could yield clues to the origin of bladder cancer. (Fox Chase Cancer Center)

"Full House" actor revealed on his podcast that he has stage III non-Hodgkin lymphoma. (USA Today)

Remote proved accurate for diagnosing melanoma. (NYU Langone Health, Journal of the American Academy of Dermatology)

Comment